Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salbutamol MDI - GSK

Next Previous
X
Search
Drug Profile

Salbutamol MDI - GSK

Alternative Names: AH-3365; Albuterol; Albuterol HFA; albuterol hydrofluoroalkane; salbutamol (albuterol) MDI; salbutamol - metered dose; Salbutamol HFA; Salbutamol hydrofluoroalkane; salbutamol pressurised inhalation; VENTOLIN HFA

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GSK
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma

Most Recent Events

  • 19 Feb 2024 Preclinical trials in Asthma in United Kingdom (PO)
  • 15 Feb 2024 GSK plans a phase III trial for Asthma (In adolescents, In adults, In the elderly) in US, Argentina, Canada, France, Greece, Italy, Panama, Poland, United Kingdom (PO, Inhalant) (NCT06261957) (EudraCT2023-509001-76-00)
  • 07 Feb 2024 Phase-III clinical trials in Asthma (PO) prior to February 2024 (GSK pipeline, February 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top